Extracellular targeting of cell signaling in cancer : strategies directed at MET and RON receptor tyrosine kinase pathways / / edited by James W. Janetka, Roseann Benson

• Pubblicazione: Hoboken, New Jersey : , : John Wiley & Sons, , 2018; ©2018
• Descrizione fisica: 1 online resource (485 pages)
• Disciplina: 362.1969940072
• Soggetto topico: Metastasis - Treatment - Technological innovations; Cancer - Treatment - Technological innovations; Tumor suppressor proteins - Research; Protein-tyrosine kinase
• Soggetto genere / forma: Electronic books.
• Persona (resp. second.): JanetkaJames W. <1968->; BensonRoseann
• Nota di bibliografia: Includes bibliographical references and index.
• Nota di contenuto: Discovery and function of the HGF/MET and the MSP/RON kinase signaling pathways in cancer / Silvia Benvenuti, Melissa Milan, and Paolo Comoglio -- The role of HGF/MET and MSP/RON signaling in tumor progression and resistance to anticancer therapy / Lidija Klampfer, Ben Yaw Owusu -- HGF activator (HGFA) and its inhibitors HAI-1 and HAI-2 : key players in tissue repair and cancer / Hiroaki Kataoka and Takeshi Shimomura -- Physiological functions and role of matriptase in cancer / Thomas E. Hyland, Karin List, and Fausto A. Varela -- The cell-surface, transmembrane serine protease hepsin : discovery, function and role in cancer / Denis Belitskin, Juha Klefström, Shishir Pant, and Topi Tervonen -- Targeting HGF with antibodies as an anticancer therapeutic strategy / Donald Bottaro, Dinuka M De Silva, and Arpita Roy -- MET and RON receptor tyrosine kinases as therapeutic antibody targets for cancer / Ling Liu, Mark Wortinger, Jonathan Tetreault, and Nick Loizos -- Inhibitory antibodies of the proteases HGFA, matriptase, and hepsin / Daniel Kirchoffer, Robert Lazarus, and Charles Eigenbrot -- Inhibitors of the growth-factor activating proteases matriptase, hepsin and HGFA : strategies for rational drug design and optimization / Robert Galemmo, James Janetka -- Cyclic peptide serine protease inhibitors based on the natural product SFTI-1 / Ashley Buckle, David E. Hoke, Olga Ilyichova, Blake T. Riley, Jonathan M. Harris -- Screening combinatorial peptide libraries in protease inhibitor drug discovery / Paulina Kasperkiewicz, Marcin Poreba, Sanford Burnham Prebys, Marcin Drag and Wioletta Rut -- Chemical probes targeting proteases for imaging and diagnostics in cancer / Pedro Gonçalves and Steven Verhelst -- Cancer diagnostics of protease activity and metastasis / John Beard and Timothy O'Brien -- Roles of pericellular proteases in tumor angiogenesis : therapeutic implications / Janice Kraniak, Raymond R. Mattingly, and Bonnie Sloane.
• Sommario/riassunto: International experts present innovative therapeutic strategies to treat cancer patients and prevent disease progressionExtracellular Targeting of Cell Signaling in Cancer highlights innovative therapeutic strategies to treat cancer metastasis and prevent tumor progression. Currently, there are no drugs available to treat or prevent metastatic cancer other than non-selective, toxic chemotherapy. With contributions from an international panel of experts in the field, the book integrates diverse aspects of biochemistry, molecular biology, protein engineering, proteomics, cell biology, pharmacology, biophysics, structural biology, medicinal chemistry and drug development.A large class of proteins called kinases are enzymes required by cancer cells to grow, proliferate, and survive apoptosis (death) by the immune system. Two important kinases are MET and RON which are receptor tyrosine kinases (RTKs) that initiate cell signaling pathways outside the cell surface in response to extracellular ligands (growth factors.) Both kinases are oncogenes which are required by cancer cells to migrate away from the primary tumor, invade surrounding tissue and metastasize. MET and RON reside on both cancer cells and the support cells surrounding the tumor, called the microenvironment. MET and RON are activated by their particular ligands, the growth factors HGF and MSP, respectively. Blocking MET and RON kinase activation and downstream signaling is a promising therapeutic strategy for preventing tumor progression and metastasis. Written for cancer physicians and biologists as well as drug discovery and development teams in both industry and academia, this is the first book of its kind which explores novel approaches to inhibit MET and RON kinases other than traditional small molecule kinase inhibitors. These new strategies target key tumorigenic processes on the outside of the cell, such as growth factor activation by proteases. These unique strategies have promising potential as an improved alternative to kinase inhibitors, chemotherapy, or radiation treatment.
• Altri titoli varianti: Extracellular targeting of cell signaling in cancer
• Titolo autorizzato: Extracellular targeting of cell signaling in cancer
• ISBN: 1-119-30021-5; 1-119-30020-7; 1-119-30022-3; 9781119300182; 9781119300229
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Lingua di pubblicazione: Inglese
• Record Nr.: 9910270878903321
• Lo trovi qui: Univ. Federico II